Ibotta's 6% Exit-Growth Target Passes the Smell Test-But Q3's Dip Could Spoil the Pop

Ibotta has rebuilt credibility, but the stock is now testing that recovery

Ibotta has given investors a reason to take the turnaround seriously. After more than a year of contraction, it delivered a return to revenue growth in Q2, with revenue of $88.9 million, 3% year-over-year growth, and adjusted EBITDA of $16.5 million. The market responded accordingly: shares rose 15.91% in after-hours trading.

That reaction does not mean the story is fully proved. It means the company finally gave buyers something more trustworthy: evidence that business fundamentals are stabilizing. For now, Ibotta trades more as a credibility-and-demand recovery story than as a company with a fully confirmed growth runway.

Q3 matters because it tests whether the turnaround is repeatable

Ibotta now guides to $86 million to $90 million in Q3 revenue, or roughly 6% growth at the midpoint. Management also still expects modest sequential growth in Q4 and to exit 2026 at mid-single-digit year-over-year growth.

That makes the next quarter more important than the post-earnings excitement. The stock has already absorbed some hope that the business is back on solid ground. The next step is proof that the growth streak is more than a one-quarter relief move. If Ibotta delivers another quarter of growth and holds the end-of-year target, the recovery narrative stays intact. If not, investors may decide the turnaround story got ahead of itself.